Aggressive course of atherosclerosis in hyperlipoproteinemia (a): a case series-Reference-Cited by-同舟云学术

Aggressive course of atherosclerosis in hyperlipoproteinemia (a): a case series

Published:2023-12-28 Issue:6 Volume:19 Page:591-596
ISSN:2225-3653
Container-title:Rational Pharmacotherapy in Cardiology
language:
Short-container-title:Racionalʹnaâ farmakoterapiâ v kardiologii

Author:

Namitokov A. M.¹^ORCID,Zaphiraki V. K,²^ORCID,Donets E. K.³^ORCID,Malyarevskaya O. B.³^ORCID,Karabakhtsieva K. V.²^ORCID,Yahutl A. N.⁴^ORCID

Affiliation:

1. Research Institute — Ochapovsky Regional Clinical Hospital № 1; Kuban State Medical University

2. Kuban State Medical University

3. Research Institute — Ochapovsky Regional Clinical Hospital № 1

4. Adygeya Republic Clinical Hospital

Abstract

Currently, worldwide interest in lipoprotein(a) (LP(a) as one of the most important markers of premature and aggressive atherosclerosis is steadily growing. This trend is due to both the new data on the pathogenesis of hyperlipoproteinemia (a) and the development of novel treatment methods in the near future. The variety of clinical manifestations of atherosclerosis associated with high LP(a) concentrations leads such patients to specialists of various profiles. The aim of this paper was to demonstrate, using examples from the practice of two lipid centers in Krasnodar, the diversity of clinical scenarios of atherosclerosis as a systemic disease in patients with very high LP(a) levels, as well as to highlight the current and future options for the treatment of hyperlipoproteinemia (a).

Publisher

Silicea - Poligraf

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine

Reference20 articles.

1. Berg K. A new serum type system in man--the LP system. Acta Pathol Microbiol Scand. 1963;59:369-382. DOI:10.1111/j.1699-0463.1963.tb01808.x.

2. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331-2339. DOI:10.1001/JAMA.2009.801.

3. Zueva IB, Baratashvili GG, Krivonosov DS, Buch AV, Sidorkevich SV. Modern ideas about the role of lipoprotein (a) in the development of cardiovascular events. The possibilities of therapy. Arterial’naja gipertenzija. 2016;22(3):232–243. (In Russ) DOI:10.18705/1607-419X-2016-22-3-232-243.

4. Koschinsky ML. Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein. Curr Atheroscler Rep. 2005;7(5):389-395. DOI:10.1007/s11883-005-0052-y.

5. Koschinsky ML. Novel Insights Into Lp(a) Physiology and Pathogenicity: More Questions Than Answers? Cardiovasc Hematol Disord Drug Targets. 2006;6(4):267-278. DOI:10.2174/187152906779010764.